NVO
Novo Nordisk A/S Sponsored ADR Class B · NYSE:NVO
40.00 USD0.8600 +2.20%
Novo Nordisk A/S Sponsored ADR Class B (NYSE:NVO) last traded at 40.00 USD, up 2.20% on the day. Over the past year the stock is down 19.92%. Its 52-week range is 35.12 to 64.16. It is in the Health Technology sector (Pharmaceuticals: Major).
Key statistics
Open39.61
Day range39.54 – 40.10
52-week range35.12 – 64.16
Volume15.28 M
Average volume (10 days)9.33 M
Market cap175.64 B
P/E9.78
EPS (TTM)4.09
Dividend yield3.08%
Beta (1 year)0.8379
Revenue (TTM)51.45 B
Employees68.79 K
Performance
+2.01%1 week
+5.12%1 month
−15.61%3 months
−7.64%6 months
−22.50%Year to date
−19.92%1 year
Technical rating
Buy
Daily summary of 11 oscillators and 15 moving averages. See every indicator
Analysts’ target
49.66 USD
The average 1-year price target, +24.16% from the last price. See the forecast
Latest headlines
- Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up NextStocktwits · 02 Nov 2026
- Jobs, Midterm Elections, Apple, Palantir, McDonald's, Moderna, and More to Watch This Week — Barrons.comDow Jones Newswires · 01 Nov 2026
- Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growthSeeking Alpha · 31 Oct 2026
- Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on CancerBenzinga · 29 Oct 2026
- Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trialReuters · 28 Oct 2026
- Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible (UPDATED)Benzinga · 28 Oct 2026
- LLY Vs NVO: Lilly’s Retatrutide Beats Novo’s Ozempic In Head-To-Head Trial — Retatrutide More Than Doubles Weight LossStocktwits · 28 Oct 2026
- Lilly's next-gen drug outshines Ozempic on weight loss, blood sugar control in trialReuters · 28 Oct 2026
Market data from TradingView’s public feed, delayed as the exchange requires. For study only, not investment advice.